ImmunoGen, Inc. (NASDAQ: IMGN) is a biotechnology company focused on the development of anti-drug therapy (ADC) for cancer treatment. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.An ImmunoGen ADC contains an antibody made associated with a goal found on cancer cells, with one of the company's powerful agents to kill cells attached as a "load". The antibody delivers a cell-killing agent specifically to the cancer cells that carry their target and the load kills these cells. In some cases, the antibody also has anticancer activity. Currently certified ADCs with ImmunoGen technology employing one of the company's agents killing maytansinoid cells, either DM1 or DM4, or one of the company's DNA-based loads. anetumab ravtansine (BAY94-9343) targeting mysothelin (for the treatment of mesothelioma), starting with the second phase trial in 2016 mirthoksimab soravtansineGenImmuno also developed isatuximab, a monoclonal antibody without linking it to toxins.